Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Celebrates Two-Year Anniversary of COFEPRIS Approval to Import its CBD Hemp Oil Products

Medical Marijuana,Inc.
Posted on: 22 Feb 18
Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Celebrates Two-Year Anniversary of COFEPRIS Approval to Import its CBD Hemp Oil Products

PR Newswire

SAN DIEGO, Feb. 22, 2018

SAN DIEGO, Feb. 22, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, subsidiary HempMeds®Mexico celebrates the second anniversary of its historic permits granted by Mexico's Federal Commission for Protection Against Health Risks, COFEPRIS. These permits opened doors for the development of a new cannabis product market in Mexico and broadened access to cannabidiol (CBD) hemp oil to Mexicans in need.

Those first permits, granted in February 2016, allowed for families to import the Company's CBD hemp oil, Real Scientific Hemp Oil™-X (RSHO-X™). This product has no psychoactive ingredients and complies with current national regulations. Maria Paula and Alina were the first two children to have legal access to these products, and since, hundreds of Mexicans have benefited from the same health and wellness benefits of CBD.

Since February 2017, COFEPRIS has granted hundreds of permits for importing HempMeds®Mexico's RSHO-X™. HempMeds®Mexico was the first company approved by COFEPRIS to distribute its CBD hemp oil products. These products are available through an import process established by COFEPRIS, which requires a medical prescription and importation approval.

"We are proud to be the first company to work with Mexican cannabis and health experts to show the safety and efficiency of RSHO-X™," said HempMeds® President of Latin America, Raul Elizalde. "Our operations in Mexico are growing daily and now we are waiting for the government's secondary cannabis regulation that will allow the importation of CBD products that have trace amounts of THC. We hope that Mexican authorities will consider the research that has been conducted by leading doctors and scientists and also the recommendation made by the World Health Organization in November 2017 to not schedule CBD as a drug."

"HempMeds Mexico has been one of our fastest-growing subsidiaries and has taken the cannabis industry in Mexico by storm," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "We look forward to growth in the country and in other Latin American countries as well."

Since the establishment of HempMeds®Mexico, the Company has worked to promote access to CBD products by supporting non-profit organizations that help provide quick access and by working with the government to establish an importation process that allows patients to get RSHO-X™ with ease.

About HempMeds® Mexico

HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company's website at:

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit

To see Medical Marijuana, Inc.'s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

Public Relations Contact:
Andrew Hard
Chief Executive Officer CMW Media
P. 858-264-6600


View original content:

SOURCE Medical Marijuana, Inc.

PR Newswire

Last updated on: 22/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.